Condition: Colorectal Cancer · Ovarian Cancer · Gastric Cancer · Sponsor: Hadassah Medical Organization
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.
This description comes directly from the study's public registry record.
Hani Steinberg, R.N. B.A. · : 00 972 50 7874292 · hanis@hadassah.org.il
Tamar Peretz, MD · 00 972 2 6777825 · tamary@hadassah.org.il
Always discuss trial participation with your own doctor first.
| Hadassah Medical Organization | Jerusalem, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00722228